Trials / Completed
CompletedNCT00185848
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sanjiv Sam Gambhir · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether \[18F\]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of \[18F\]FHBG in patients.
Detailed description
The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | [18F]FHBG | \< 7mCi and 2 ug, iv |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2005-09-16
- Last updated
- 2017-03-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00185848. Inclusion in this directory is not an endorsement.